Association of Sodium-Glucose Cotransporter-2 Inhibitor Use with Laboratory- and Anthropometry-Derived Indices of Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Retrospective Cohort Study

Abstract Sodium-glucose cotransporter-2 inhibitors lower body weight, and their association with liver steatosis and fibrosis scores in routine practice is uncertain. We performed a retrospective cohort study of 493 adults with type 2 diabetes of at least 5 years’ duration at a tertiary hospital in Türkiye. Of these, 268 adults initiated a sodium-glucose cotransporter-2 inhibitor (dapagliflozin or empagliflozin) and used it regularly for at least 6 months, and 225 adults continued other therapies. All patients underwent liver ultrasonography. We compared 6-month changes in the hepatic steatosis index, the visceral adiposity index, the triglyceride-glucose index, the fibrosis-4 index and the aspartate aminotransferase-to-platelet ratio index. Analyses used regression with prespecified clinical covariates, inverse probability weighting and propensity score matching. The hepatic steatosis index fell more in the inhibitor group (adjusted difference: −0.69, 95% confidence interval: −1.13 to −0.25, p=0.002; weighting: −0.73; matching: −0.61). The body weight fell by 2.26 kg more (95% confidence interval: −2.70 to −1.83). The ratio of alanine to aspartate aminotransferase did not differ between groups. After adding the change in body weight to the model, the difference in the hepatic steatosis index disappeared (0.12, 95% confidence interval: -0.35 to 0.58). The fibrosis-4 index was slightly lower in the inhibitor group (adjusted difference: -0.13, 95% confidence interval: -0.19 to -0.08), whereas the other three indices did not differ clearly after adjustment. In this cohort, the lower hepatic steatosis index with these drugs reflects weight loss, and the index gives little separate information on liver fat.

Authors

Institutions

Publication Details

Journal
Hormone and Metabolic Research
Published
2026-11-13
DOI
https://doi.org/10.1055/a-2994-0940
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association of Sodium-Glucose Cotransporter-2 Inhibitor Use with Laboratory- and Anthropometry-Derived Indices of Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Retrospective Cohort Study

Hatice Hamarat, Özge Alkan Tali, Banu Kara Kıvanç, Zeynep Irmak Kaya et al.
Hormone and Metabolic Research
Liver Disease Diagnosis and Treatment
article

Association of Sodium-Glucose Cotransporter-2 Inhibitor Use with Laboratory- and Anthropometry-Derived Indices of Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Retrospective Cohort Study

Hatice Hamarat, Özge Alkan Tali, Banu Kara Kıvanç, Zeynep Irmak Kaya, Osman Son, Eren Son
article en

Abstract

Abstract Sodium-glucose cotransporter-2 inhibitors lower body weight, and their association with liver steatosis and fibrosis scores in routine practice is uncertain. We performed a retrospective cohort study of 493 adults with type 2 diabetes of at least 5 years’ duration at a tertiary hospital in Türkiye. Of these, 268 adults initiated a sodium-glucose cotransporter-2 inhibitor (dapagliflozin or empagliflozin) and used it regularly for at least 6 months, and 225 adults continued other therapies. All patients underwent liver ultrasonography. We compared 6-month changes in the hepatic steatosis index, the visceral adiposity index, the triglyceride-glucose index, the fibrosis-4 index and the aspartate aminotransferase-to-platelet ratio index. Analyses used regression with prespecified clinical covariates, inverse probability weighting and propensity score matching. The hepatic steatosis index fell more in the inhibitor group (adjusted difference: −0.69, 95% confidence interval: −1.13 to −0.25, p=0.002; weighting: −0.73; matching: −0.61). The body weight fell by 2.26 kg more (95% confidence interval: −2.70 to −1.83). The ratio of alanine to aspartate aminotransferase did not differ between groups. After adding the change in body weight to the model, the difference in the hepatic steatosis index disappeared (0.12, 95% confidence interval: -0.35 to 0.58). The fibrosis-4 index was slightly lower in the inhibitor group (adjusted difference: -0.13, 95% confidence interval: -0.19 to -0.08), whereas the other three indices did not differ clearly after adjustment. In this cohort, the lower hepatic steatosis index with these drugs reflects weight loss, and the index gives little separate information on liver fat.

Hormone and Metabolic Research
Ministry of Health (TR), Eskişehir City Hospital (TR)
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon